What Is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue comprising the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid moiety conjugated at the N-terminus. This structural modification confers resistance to dipeptidyl peptidase IV (DPP-IV), the enzyme responsible for rapid proteolysis of the His-Ala N-terminal dipeptide common to GHRH family peptides, significantly extending plasma half-life compared to native GHRH(1-44) or the truncated Sermorelin fragment.
Mechanistically, Tesamorelin acts as a full agonist at the GHRH receptor (GHRHR) expressed on anterior pituitary somatotroph cells, stimulating intracellular cAMP accumulation and protein kinase A activation, leading to pulsatile GH secretion. Downstream GH action promotes hepatic IGF-1 synthesis and systemic growth factor signalling. Research models have examined Tesamorelin in adipose tissue metabolism, lipogenesis pathways, hypothalamic-pituitary-somatotropic axis characterisation, and comparative GHRH-receptor pharmacology.
For GHRH(1-29) fragment research, see Sermorelin (SMO5 / SMO10). For dual GHRH+GHSR research, see CJC-1295 + Ipamorelin blend (CP10). For research use only.
Tesamorelin Products
Supplied as lyophilised powder in boxes of 10 research-grade vials.
GHRH Analogue Comparison
| Compound | Sequence | DPP-IV Resistance | Half-life |
|---|---|---|---|
| Sermorelin | GHRH(1-29) | Minimal | ~10-20 min |
| Tesamorelin | GHRH(1-44) + N-hex | Moderate | ~26-38 min |
| CJC-1295 (DAC) | GHRH(1-29) + DAC | High (albumin-bound) | ~6-8 days |
For research reference only. Values based on published preclinical pharmacokinetic data.
Quality Assurance
Frequently Asked Questions
Where can I buy Tesamorelin in Australia?
Eternal Peptides Wholesale is an Australian-owned, ABN-registered wholesale distributor. TM10 (Tesamorelin 10mg, box of 10) is $891.00. Every batch carries a Janoshik Analytical COA. Orders dispatched within 1-2 business days from Australia. For research use only.
What is the mechanism of action of Tesamorelin?
Tesamorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating adenylyl cyclase via Gฮฑs, increasing intracellular cAMP, and activating PKA. This drives pulsatile GH exocytosis. The trans-3-hexenoic acid N-terminal modification prevents DPP-IV cleavage at the His1-Ala2 bond, extending plasma stability. Downstream GH binding at hepatic receptors drives IGF-1 synthesis and systemic anabolic signalling. For research use only.
How does Tesamorelin compare to other GHRH analogues?
Sermorelin (GHRH 1-29) is the minimal active fragment; Tesamorelin uses the full 44-AA sequence with added DPP-IV stability; CJC-1295 with DAC binds plasma albumin for multi-day half-life. Tesamorelin's full-sequence design means it retains all receptor contact residues with moderate plasma stability โ a different pharmacokinetic profile than either the short-acting Sermorelin or the depot-type CJC-1295 DAC. For research use only.
How is Tesamorelin tested?
Every batch is independently tested by Janoshik Analytical. Tests include HPLC purity, mass spectrometry identity confirmation, USP sterility, LAL endotoxin, and ICP-MS heavy metals. The COA is published on the product page and independently verifiable at janoshik.com. COA documentation included with every order. For research use only.